Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults

ABSTRACT: Abstract

Background

In the ZOE-50 and ZOE-70 clinical trials, the candidate herpes-zoster subunit vaccine (HZ/su; 50µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) demonstrated high efficacy against HZ, with limited waning over 4 years and consistent efficacy across age cohorts. In adults ≥60 years of age, the immune responses elicited by 2 HZ/su doses administered 2 months apart persisted for at least 6 years.1 Here we report immunogenicity and safety 9 years post-initial vaccination.

Methods

This Phase IIIB, open, long-term extension study (NCT02735915) followed 70 participants who received 2 HZ/su doses in the initial trial (NCT00434577). Blood samples to evaluate the persistence of cellular (intracellular cytokine staining) and humoral (ELISA)

SUBMITTER: Pauksens K 

PROVIDER: S-EPMC5631129 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature